AstraZeneca, AI biologics firm Absci tie up on cancer drug

Biotech company Absci, based in Vancouver, Washington, is teaming up with AstraZeneca to create antibody therapeutics to combat cancer. The deal is worth over $200 million.

Absci, which specializes in designing drug treatments through the application of generative AI, will be developing a generative AI model to fulfill the new deal. The partners have yet to announce the cancers they plan to treat with the vaccines.

Sean McClain, Absci’s CEO, said, “We’re proud to work closely with AstraZeneca to leverage our AI to bring novel treatments to oncology patients.”

READ THE STORY at Reuters »